I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media coverage of psychedelics business, policy, research and beyond. No aggregators, no AI bots: we manually accumulate these clippings and sprinkle in some quick-take analysis here and there. We will also send a weekly digest of the Psychedelic News Feed to…
EQRx, failed developer of low-priced cancer drugs, is sold for cash
EQRx is done, sold for its cash. The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the